Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus platinum salt with bevacizumab in metastatic collecting duct carcinoma (Phase II)
2013-001179-19Phase 2Active
- Sponsor
- Unicancer
- Start
- Jan 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, cisplatin, carboplatin and bevacizumab in collecting duct carcinoma (CDC), sponsored by Unicancer. Primary endpoints: Objective response rate (ORR) and Progression-free survival rate at 6 months. Started Jan 2015; status: active.
02
Drugs
gemcitabinecisplatincarboplatinbevacizumab
03
Conditions
collecting duct carcinoma (CDC)
Beyond the preview
Go deeper on 2013-001179-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001179-19.